|
Active substance |
nivolumab |
|
Holder |
Bristol-Myres Squibb |
|
Status |
Closed |
|
Indication |
Classical Hodgkin lymphoma in adult patients who have relapsed after ASCT and brentuximab vedotin treatment. |
|
Public documents |
|
|
Last update |
30/01/2017 |
Opdivo®
Last updated on 13/09/2024